New strategies in the treatment of resectable non-small cell lung cancer

References

• Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg. Clin. N Am. 67(5), 1037–1049 (1987).
   Google Scholar
• Bains MS. Surgical treatment of lung cancer. Chest 100(3), 826–837 (1991).
   PubMedGoogle Scholar
• Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individuals patients from 52 randomized clinical trials. BE Med. 311(7010), 899–909 (1995).
   Google Scholar
• ••This meta-analysis includes chemotherapytrials conducted in lung cancer patients between 1965 and 1991.
   Google Scholar
• Keller SM, Adak S, Wagner H etal. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl. Med. 343(17), 1217–1222 (2000).
   Google Scholar
• ••Keller et aL published the largestrandomized postoperative adjuvant trial to date in patients with completely resected stages II and IIIA NSCLC.
   Google Scholar
• PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 352(9124), 257–263 (1998).
   PubMedGoogle Scholar
• •Results of a meta-analysis of nine trials including resected stages I-IIIA NSCLC patients who were randomized to either radiotherapy or no further treatment.
   Google Scholar
• Martini N, Kris MG, Flehinger BJ et al. Preoperative chemotherapy for stage Ma (N2) lung cancer: The Sloan-Kettering experience with 136 patients. Ann. Thorac. Surg. 55(6), 1365–1374 (1993).
   Google Scholar
• ••One of the earliest preoperative combination chemotherapy programs developed in stage IIIAN2 NSCLC patients.
   Google Scholar
• Burkes RL, Ginsberg RJ, Shepherd FA et al. Induction chemotherapy with mitomycin, vindesin and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II trial. 1 Clin. Oncol 10(4), 580–586 (1992).
   Google Scholar
• •Toronto investigators performed a Phase II study using mitomycin/vinblastine/ cisplatin chemotherapy prior to surgery in stage IIIAN2 disease.
   Google Scholar
• Sugarbaker DJ, Herndon J, Kohman LJ, Krasna MJ, Green MR. Results of Cancer and Leukemia Group B Protocol 8935, a multi-institutional Phase II trimodality trail for stage IIIA(N2) non-small-cell lung cancer. j Thorac. Carcliovasc. Surg. 109(3), 473–485 (1995).
   Google Scholar
• ••In a multi-institutional study, the Cancerand Leukemia Group B tested pre- and postoperative chemotherapy with vinblasine/cisplatin in stage IIIAN2 disease.
   Google Scholar
• Rosell R, Gómez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl. Med 330(3), 153–158 (1994).
   Google Scholar
• Roth JA, Fossella F, Komaki R et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J. Natl Cancer Inst. 86(9), 673–680 (1994).
   Google Scholar
• Rosell R, Gomez-Codina J, Camps C et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: definitive analysis of a randomized controlled trial. Lung Cancer26(1), 7–14 (1999).
   PubMed Web of Science ®Google Scholar
• ••This report presents long-term survival ofpatients included in the randomized trial comparing surgery versus preoperative chemotherapy followed by surgery in stage 111A disease.
   Google Scholar
• Roth JA, Atkinson EN, Fossella F et al Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21(1),1–6 (1998).
   PubMed Web of Science ®Google Scholar
• ••The increase in survival conferred by perioperative chemotherapy was maintained during extended observation period with 5-year survival rates for perioperative chemotherapy of 36%.
   Google Scholar
• Albain KS, Rusch VW Crowley JJ et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group Phase II study 8805.1 Clin. Oncol 13(8), 1880–1892 (1995).
   Google Scholar
• ••Phase IT trial analyzing preoperativeetoposide/cisplatin plus concurrent chemotherapy in stage IIIA/BIB disease.
   Google Scholar
• Albain K, Rush V, Crowley J et al. Long- term survival after concurrent cisplatin/ etoposide (PE) plus chest radiotherapy (RI) followed by surgery in bulky, stages IIIA(N2) and IIIB non-small cell lung cancer (NSCLC): 6-year outcomes from Southwest Oncology Group Study 8805. Proceedings of the 35th American Society of Clinical Oncology Atlanta, USA, 1801 (1999).
   Google Scholar
• Choi NC, Carey RVV, Daly W et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. I Clin. Oncol 15(2), 712–722 (1997).
   Google Scholar
• Eberhardt W Wilke H, Stamatis G eta Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definite surgery in locally advanced non-small-cell lung cancer: Mature results of a Phase II trial. I Clin. Oncol 16(2), 622–634 (1998).
   Google Scholar
• •• Patients with stage IIIA and IIIB received four cycles of preoperative etoposide/cisplatin, three before radiation theerapy and the fourth was combined with hyperfractionated radiotherapy.
   Google Scholar
• Thomas M, Rube C, Semik M et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. j Clin. Oncoll7 (4), 1185–1193 (1999).
   Google Scholar
• Fleck J, Camargo J, Godoy D et al. Chemoradiation therapy alone yersus chemotherapy alone as a neoadjuvant treatment for stage III non-small cell lung cancer: Preliminary report of a Phase III randomized trial. Proceedings of the 29th American Society of Clinical Oncology Orlando, USA, 1108 (1993).
   Google Scholar
• Rosell R. The integration of newer agents into neoadjuvant therapy. Semin. aryl 25 (3 Suppl. 8), 24–27 (1998).
   Google Scholar
• Van Zandwijk N, Smit EF, Kramer GW et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIAN2 non-small-cell lung cancer: A Phase II study of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol 18(14), 2658–2664 (2000).
   Google Scholar
• Betticher DC, Hsu Schmitz SF, Gauthier Y et al Neoadjuvant chemotherapy with docetaxel (DOC, taxotere) and cisplatin (cis) in patients (pts) with non-small cell
   Google Scholar
• Mattson KV, Ten Velde G, Krofta K et al Taxotere as neoadjuvant therapy for radically-treatable stage III NSCLC. Preliminary results of an international Phase III study. Proceedings of the 36th American Society of Clinical Oncology New Orleans, USA, 1890 (2000).
   Google Scholar
• Rosell R, Felip E. Role of multimodality treatment for lung cancer. Sernin. Surg. Oncol 18 (2), 143–151 (2000) .
   Google Scholar
• Andre F, Grunenwald D, Pignon JP et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J. Clin Oncol 18(16), 2981–2989 (2000). This study analyzed prognostic factors in 702 patients with resected N2 disease.
   Google Scholar
• Martin J, Abolhoda A, Bains MS et al. Long-term results of combined modality therapy in resectable non-small cell lung cancer (NSCLC). Proceedings of the 37th American Society of Clinical Oncology San Francisco, USA, 1240 (2001).
   Google Scholar
• Bueno R, Richards WG, Swanson SJ et al Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann. Thorac. Surg 70(6), 1826–1831 (2000).
   Google Scholar
• Pisters KM, Ginsberg RJ, Giraux DJ et al. Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. Thorac. Canlioyasc. Surg. 1199(3)429-439 (2000). Multicenter Phase II trial in which 94 patients with T2NO, T1-2N1 and T3NO-1 NSCLC received two cycles of induction paclitaxel/carboplatin followed by surgery and then three additional cycles of the same chemotherapy. In this study preoperative chemotherapy is feasible and produces a high response rate with acceptable morbidity in early-stage NSCLC.
   Google Scholar
• Depierre A, Milleron B, Moro D et al. Phase III trial of neo-adjuvant chemotherapy (NCT) in resectable stage I (except T1N0), II, Ma non-small cell lung cancer: The French experience. Proceedings of the 35th American Society Clinical Oncology Atlanta, USA, 1792 (1999).
   Google Scholar
• Rosell R, Carrato A. From the bench to the bed: the need for translational research. Rev aryl 4,181–187 (1999).
   Google Scholar
• Monk) M, Rosell R, Sanchez JJ et al. Paclitaxel resistance in non-small cell lung cancer associated with I3-tubulin gene mutations. Clin. Oncoll7 (6), 1786–1793 (1999). Monzó et al have identified 13-tubulin mutations in 33% of NSCLC patients and none of the patients with mutations had an objective response to paclitaxel treatment.
   Google Scholar
• Rosell R, Danenberg K, Gandara D et al. Altered ERCC1 expression correlates with response to cisplatin (DDP) + gemcitabine (gem) in non-small-cell lung cancer (NSCLC) patients (pts). Proceedings of the 37th American Society of Clinical Oncology San Francisco, USA, 1300 (2001).
   Google Scholar
• Rosell R, Monk) M, Sanchez JJ et al. 13- Tubulin mutations in circulating extracellular DNA of non-small-cell lung cancer (NSCLC) patients (pts). Proceedings of the 36th American Society of Clinical Oncology New Orleans, USA, 1897 (2000).
   Google Scholar
• Rosell R, Taron M, OBrate A. Predictive molecular markers in non-small cell lung cancer. CUI7: Opin. Oncol (2001) (In Press).
   Google Scholar
• Miller VA, Johnson D, Heelan RT et al. A pilot trial demonstrates the safety of ZD1839 (Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC). Proceedings of the 37th American Society of Clinical Oncology San Francisco, USA, 1301 (2001).
   Google Scholar
• Perez-Soler R, Chachoua A, Huberman M et al A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proceedings of the 37th American Society of Clinical Oncology San Francisco, USA, 1235 (2001).
   Google Scholar
• Johnson DH, DeVore R, Kabbinavar F et al Carboplatin (C) + Paclitaxel (T) + RHUMAB-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proceedings of the 37th American Society of Clinical Oncology San Francisco, USA, 1256 (2001).
   Google Scholar
• Rosell R, Cortés-Funes H, Monk) M et al. TRAIL/Apo-2L Death signaling pathway: implications for chemoresistance. Rev Oncol (In Press).
   Google Scholar